Sometimes a changing of the guard by bringing on board persons who have the same vision of a Company is needed in order to stimulate growth and capitalize on the mission statement. Viropro Inc. (VPRO) did just that after Friday’s trading session when they reported three new replacement members to their Board of Directors, all of which are well seasoned. Couple the change with the efforts to update their current financial reports, and VPRO could be a huge winner as it sits at under a penny with 2011 revenues that more than half their shares outstanding held by insiders.
Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
VPRO Stock Chart
Market Cap: 7.60M
Close: 0.0083, down -0.0001 (-1.19%)
Volume: 937,647
Dollar Volume: $7,419
High: 0.0088
Low: 0.0071
Trades: 17
Average Trade Size: 55,155
Authorized: 1,000,000,000
Issued and Outstanding: 916,089,570
Looking for Hot Penny Stocks?
Click here and get Alerts on the Best Penny Stocks FREE
Per the 8-K filed after Friday’s trading session ended: On October 17, 2012, Emilio Binavince and Dr. Scott Brown resigned as members of the Viropro Board of Directors only to be followed two days later by the resignation of Dr. Rajiv Datar leaving current Chairman and Ceo, Ms. Cynthia Tsai, as the Company’s only remaining director. Tsai wouldn’t be lonely for long as Kenneth A. Sorensen, Ph.D., Dr. Ann Rose and Ms. Michelle Peake were appointed to join her on the revenue generating biotech’s board.
Of the three new appointees, Dr. Ann H. Rose, currently President and CEO of ViCro, a boutique consulting company, could be the biggest addition to Viropro with the largest impact on VPRO stock in the future. Rose’s ViCro is focused on assisting companies and academic institutions bring their biomedical products expeditiously through the regulatory approval and/or compliance processes and onto the world market.
Dr. Rose, as well as the other two new appointees, are a breathe of fresh air for the biopharmaceuticals producer. Although the company is nearly one year past due on their financial filings, looking into their last 10-Q for the quarter ended September 30, 2011, it’s clear that they were on the right track. Revenues for the three and nine months ended were reported to be $385,156 and$839,328, respectively, compared to $175,851 and $397,280 for the same periods in 2011, respectively. Basically, revenues for the three months ended September 30, 2011 were nearly equal to the revenues for the entire nine months ended September 30, 2010.
There is no way of being able to verify the current financial status without updated quarterlies and their 10-K for the year ended December 31, 2011. However, with the acquisitions made in 2011 which was the predominant reason for the outstanding shares increase, 523.94 million, the revenues that may have been produced since the acquisition of Alpha Biologics Sdn. Bhd. could push VPRO stock back into the territory they traded at when the acquisition was announced in early 2011. Potential Upside: 925%
About VPRO Stock
Viropro Inc., a bitechnology company, conducts operations through its subsidiaries, Viropro International Inc. , Biologics Process Development Inc. of San Diego, California, Alpha Biologics Ltd. of Cambridge, UK and Alpha Biologics Sdn. Bhd. of Penang, Malaysia. Viropro specializes in the development and manufacturing of biopharmaceutical drugs and offers services to a wide array of pharmaceutical and biotechnology companies. Additionally, it engages in the transfer of its core and proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis.
Viropro’s principal objective is to provide high-end, cost-effective Contractual Research and Manufacturing Services to biotech and biopharmaceutical companies in global markets.
Click here to view the SEC filings for VPRO.
Bottom Line: VPRO is worth a look for those who love the penny stocks with huge upside potential. Chart technicals indicate the bounce has already begun from their new 52 week low set Thursday at .007. James Bond lover’s bounced on the Skyfall of VPRO stock and are gonna ride this for the asset potential its worth.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
ShareOCT
